|
EP4793360A2
(en)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
TW201920257A
(zh)
|
2008-04-11 |
2019-06-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
CA2865158C
(en)
|
2012-02-24 |
2022-11-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
PE20150605A1
(es)
|
2012-04-27 |
2015-05-28 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
|
|
US20150203591A1
(en)
*
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスＦｃγＲＩＩ特異的Ｆｃ抗体
|
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
|
SG11201509595PA
(en)
|
2013-05-28 |
2015-12-30 |
Dcb Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
JP6693872B2
(ja)
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス，インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
HUE050159T2
(hu)
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-CD3 antitestek és alkalmazási eljárások
|
|
ES2884930T3
(es)
*
|
2014-03-26 |
2021-12-13 |
Siemens Healthcare Diagnostics Inc |
Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y métodos de producción y uso de los mismos
|
|
EP3613433B1
(en)
*
|
2014-05-30 |
2022-01-05 |
Shanghai Henlius Biotech, Inc. |
Anti-epidermal growth factor receptor (egfr) antibodies
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
US11820832B2
(en)
|
2014-07-25 |
2023-11-21 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
|
MX386342B
(es)
*
|
2014-07-25 |
2025-03-18 |
Memorial Sloan Kettering Cancer Center |
Móleculas de unión a her2 y cd3 biespecíficas.
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
ES2808853T3
(es)
|
2014-11-20 |
2021-03-02 |
Hoffmann La Roche |
Cadenas ligeras comunes y procedimientos de uso
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
CA2972800A1
(en)
|
2015-01-02 |
2016-07-07 |
Dyax Corp. |
Bispecific antibodies against plasma kallikrein and factor xii
|
|
WO2016115274A1
(en)
*
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
CN114773469B
(zh)
|
2015-02-05 |
2025-12-19 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
MA42971A
(fr)
*
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
TWI787796B
(zh)
*
|
2015-05-04 |
2022-12-21 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
|
|
BR112017023872A2
(pt)
*
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
JP6841754B2
(ja)
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
US9988454B2
(en)
*
|
2015-05-20 |
2018-06-05 |
Immunwork Inc. |
Peptide core-based multi-arm linkers for treating central nervous system diseases
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
EP3325516B1
(en)
|
2015-07-21 |
2021-12-15 |
Takeda Pharmaceutical Company Limited |
A monoclonal antibody inhibitor of factor xiia
|
|
US11466093B2
(en)
*
|
2015-07-27 |
2022-10-11 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
KR20240149974A
(ko)
*
|
2015-08-11 |
2024-10-15 |
고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 |
항체
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EA039736B1
(ru)
*
|
2015-09-15 |
2022-03-04 |
Сайтомкс Терапьютикс, Инк. |
Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения
|
|
WO2017046301A1
(en)
|
2015-09-18 |
2017-03-23 |
Nestec S.A. |
Savoury concentrates with a flowable texture based on two starches
|
|
MY206406A
(en)
|
2015-10-02 |
2024-12-16 |
Hoffmann La Roche |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
WO2017083306A1
(en)
|
2015-11-09 |
2017-05-18 |
R.P. Scherer Technologies, Llc |
Anti-cd22 antibody-maytansine conjugates and methods of use thereof
|
|
HUE054131T2
(hu)
*
|
2015-11-19 |
2021-08-30 |
Revitope Ltd |
Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
|
|
US10533157B1
(en)
|
2015-12-03 |
2020-01-14 |
Nantbio, Inc. |
Recombinant NK cells expressing co-stimulatory molecules
|
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
|
|
WO2017120534A1
(en)
*
|
2016-01-08 |
2017-07-13 |
Bioalliance C.V. |
Tetravalent anti-psgl-1 antibodies and uses thereof
|
|
EP3192810A1
(en)
*
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
JP7015244B2
(ja)
*
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
HRP20251020T1
(hr)
|
2016-05-20 |
2025-10-24 |
Harpoon Therapeutics, Inc. |
Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
HRP20251424T1
(hr)
*
|
2016-08-30 |
2025-12-19 |
Xencor, Inc. |
Bispecifična imunomodulacijska protutijela koja se vežu na kostimulacijske receptore i receptore imunosnih kontrolnih točaka
|
|
CN106632681B
(zh)
*
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
EP3529268B1
(en)
*
|
2016-10-19 |
2025-02-26 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
CA3041340A1
(en)
*
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
EP3551667A4
(en)
|
2016-12-09 |
2020-06-17 |
Seattle Genetics, Inc. |
BIVALENT ANTIBODIES MASKED BY COILS
|
|
WO2018108759A1
(en)
|
2016-12-13 |
2018-06-21 |
F. Hoffmann-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
CN108264561B
(zh)
*
|
2016-12-30 |
2021-09-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
|
|
US11046768B2
(en)
|
2017-01-27 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
MX2019010156A
(es)
*
|
2017-02-27 |
2020-01-09 |
Dragonfly Therapeutics Inc |
Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
WO2018178076A1
(en)
*
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
CN110520523A
(zh)
*
|
2017-03-29 |
2019-11-29 |
台北医学大学 |
具抗原专一性的t细胞及其用途
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
CN108690138A
(zh)
*
|
2017-04-12 |
2018-10-23 |
鸿运华宁（杭州）生物医药有限公司 |
一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
CA3064714A1
(en)
*
|
2017-05-23 |
2018-11-29 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
TW201904588A
(zh)
*
|
2017-06-25 |
2019-02-01 |
美商西雅圖免疫公司 |
引導及導航控制蛋白質之製造及使用方法
|
|
US11787863B2
(en)
*
|
2017-06-25 |
2023-10-17 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
|
SG11201912865VA
(en)
*
|
2017-06-25 |
2020-01-30 |
Systimmune Inc |
Multi-specific antibodies and methods of making and using thereof
|
|
WO2019005637A2
(en)
|
2017-06-25 |
2019-01-03 |
Systimmune, Inc. |
MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
|
|
WO2019036433A2
(en)
|
2017-08-16 |
2019-02-21 |
Bristol-Myers Squibb Company |
ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
|
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
MX2020006010A
(es)
*
|
2017-12-11 |
2020-10-16 |
Triphase Res And Development Iii Corp |
Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
CN112005304A
(zh)
|
2018-03-20 |
2020-11-27 |
西托姆克斯治疗公司 |
用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
US20210324088A1
(en)
|
2018-05-02 |
2021-10-21 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CA3099419A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
US20210353652A1
(en)
*
|
2018-06-04 |
2021-11-18 |
Trustees Of Tufts College |
Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
|
|
CN112513081A
(zh)
|
2018-06-14 |
2021-03-16 |
生物蛋白有限公司 |
多重特异性抗体构建体
|
|
KR102956533B1
(ko)
*
|
2018-07-02 |
2026-04-24 |
더 제너럴 하스피탈 코포레이션 |
항체 종양-표적화 조립 복합체
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
SG11202013248YA
(en)
*
|
2018-07-31 |
2021-02-25 |
Amgen Inc |
Pharmaceutical formulations of masked antibodies
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN119306844A
(zh)
|
2018-09-25 |
2025-01-14 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
WO2020072306A1
(en)
*
|
2018-10-01 |
2020-04-09 |
Amgen Inc. |
Methods for reducing aggregation of bispecific antibodies
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
US12590169B2
(en)
|
2018-10-11 |
2026-03-31 |
Inhibrx Biosciences, Inc. |
5T4 single domain antibodies and therapeutic compositions thereof
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
AU2019356573B2
(en)
|
2018-10-11 |
2025-12-18 |
Inhibrx Biosciences, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
|
LT3880675T
(lt)
|
2018-11-12 |
2024-12-27 |
Debiopharm International Sa |
Antibiotikų junginiai, jų gamybos būdas, farmacinės kompozicijos, kurių sudėtyje jie yra, ir jų panaudojimas
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
|
JP7137696B2
(ja)
|
2019-05-14 |
2022-09-14 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を予防するための方法および組成物
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
WO2020250940A1
(ja)
*
|
2019-06-11 |
2020-12-17 |
小野薬品工業株式会社 |
免疫抑制剤
|
|
US20220251206A1
(en)
|
2019-06-11 |
2022-08-11 |
Bristol-Myers Squibb Company |
Anti-ctla4 antibody prodruggable (probody) at a cdr position
|
|
WO2020256546A1
(en)
|
2019-06-17 |
2020-12-24 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
KR20210043475A
(ko)
|
2019-10-10 |
2021-04-21 |
주식회사 와이바이오로직스 |
다중 특이적 융합 단백질 및 이의 용도
|
|
AU2020379735A1
(en)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
N-terminal SCFV multispecific binding molecules
|
|
CN118580364A
(zh)
*
|
2019-11-06 |
2024-09-03 |
西雅图免疫公司 |
制导和导航控制蛋白及其制备和使用方法
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
WO2021097800A1
(en)
*
|
2019-11-22 |
2021-05-27 |
Abl Bio Inc. |
Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
|
|
EP4069735A1
(en)
*
|
2019-12-06 |
2022-10-12 |
OncoOne Research & Development GmbH |
Anti-oxmif/anti-cd3 bispecific antibody constructs
|
|
CR20220330A
(es)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso.
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
US11976133B2
(en)
*
|
2020-01-31 |
2024-05-07 |
Gensun Biopharma Inc. |
Bispecific T cell engagers
|
|
BR112022016550A2
(pt)
|
2020-02-21 |
2022-11-16 |
Harpoon Therapeutics Inc |
Proteínas de ligação a flt3 e métodos de uso
|
|
TWI908779B
(zh)
*
|
2020-03-17 |
2025-12-21 |
美商西雅圖免疫公司 |
引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
|
|
JP7729833B2
(ja)
*
|
2020-03-23 |
2025-08-26 |
サイトアーム カンパニー リミテッド |
武装免疫細胞を産生する際に使用するための二重特異性抗体
|
|
WO2021207657A1
(en)
|
2020-04-09 |
2021-10-14 |
Cytomx Therapeutics, Inc. |
Compositions containing activatable antibodies
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
KR20230092863A
(ko)
|
2020-06-11 |
2023-06-26 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
US12540188B2
(en)
|
2020-08-05 |
2026-02-03 |
Synthekine, Inc. |
IL10Rα/IL2Rγ synthetic cytokines
|
|
WO2022032005A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il10rb binding molecules and methods of use
|
|
MX2023001491A
(es)
|
2020-08-05 |
2023-03-08 |
Synthekine Inc |
Moleculas de union a gp130 y metodos de uso.
|
|
WO2022032023A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il23r binding molecules and methods of use
|
|
WO2022031885A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il10ra binding molecules and methods of use
|
|
WO2022031890A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Ifngr2 binding molecules and methods of use
|
|
JP7743500B2
(ja)
|
2020-08-05 |
2025-09-24 |
シンセカイン インコーポレイテッド |
Ｉｌ１０受容体結合性分子および使用方法
|
|
US20230279126A1
(en)
*
|
2020-08-05 |
2023-09-07 |
Synthekine, Inc. |
Il23 receptor synthetic cytokines and methods of use
|
|
EP4192489A4
(en)
|
2020-08-05 |
2024-12-11 |
Synthekine, Inc. |
IL2RB-BINDING MOLECULES AND METHODS OF USE
|
|
KR102846963B1
(ko)
|
2020-08-05 |
2025-08-18 |
신테카인, 인크. |
IL27Rα 결합 분자 및 사용 방법
|
|
WO2022032042A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il12 receptor synthetic cytokines and methods of use
|
|
US12122839B2
(en)
|
2020-08-05 |
2024-10-22 |
Synthekine, Inc. |
IFNGR binding synthetic cytokines and methods of use
|
|
WO2022031884A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rg binding molecules and methods of use
|
|
WO2022031929A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il12rb1-binding molecules and methods of use
|
|
EP4192502A4
(en)
|
2020-08-05 |
2024-10-09 |
Synthekine, Inc. |
Compositions and methods related to il27 receptor binding
|
|
WO2022031942A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il12rb2 binding molecules and methods of use
|
|
US20240034806A1
(en)
*
|
2020-12-09 |
2024-02-01 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EP4319814A4
(en)
*
|
2021-04-08 |
2025-03-26 |
Board of Regents, The University of Texas System |
Methods for activation and expansion of natural killer cells and combinations with bispecific antibodies
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
MX2023013851A
(es)
|
2021-05-24 |
2023-12-08 |
Provention Bio Inc |
Metodos para el tratamiento de diabetes tipo 1.
|
|
TW202330594A
(zh)
|
2021-09-29 |
2023-08-01 |
美商莫德斯醫療公司 |
抗原結合多肽、抗原結合多肽複合物及其使用方法
|
|
US20230174995A1
(en)
|
2021-10-15 |
2023-06-08 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
PE20241343A1
(es)
|
2021-10-15 |
2024-07-03 |
Cytomx Therapeutics Inc |
Complejo polipeptidico activable
|
|
JP7767613B2
(ja)
|
2021-11-15 |
2025-11-11 |
システィミューン，インコーポレイテッド |
二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
|
|
US20250136689A1
(en)
*
|
2022-02-04 |
2025-05-01 |
Duke University |
Compositions for and methods of treating hematological cancers
|
|
CN118574934A
(zh)
*
|
2022-02-11 |
2024-08-30 |
因特尔乌斯生物治疗公司 |
促融合弹状病毒糖蛋白及其用途
|
|
CN114316062B
(zh)
*
|
2022-03-02 |
2022-06-07 |
珠海臻谱基因科技有限公司北京分公司 |
靶向HIV gp120蛋白和人CD3分子的多特异性抗体及其应用
|
|
AU2023254206A1
(en)
|
2022-04-13 |
2024-10-17 |
Genentech, Inc. |
Pharmaceutical compositions of mosunetuzumab and methods of use
|
|
WO2024104988A1
(en)
*
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with activatable effector domain
|
|
CN116724057A
(zh)
*
|
2022-11-28 |
2023-09-08 |
浙江时迈药业有限公司 |
蛋白酶可切割的重组双特异性抗体和组合物及其用途
|
|
WO2025036848A1
(en)
|
2023-08-11 |
2025-02-20 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Anti-muc16 antibodies and uses thereof
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
KR20260056204A
(ko)
|
2023-08-14 |
2026-04-24 |
보로 테라퓨틱스, 인코포레이티드 |
표적 세포에 대한 골수 세포 활성을 조건부로 촉진시키는 치료용 결합제 및 이의 용도
|
|
TW202540200A
(zh)
|
2023-12-01 |
2025-10-16 |
美商基利科學股份有限公司 |
抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
|
|
WO2025189116A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Synthetic Design Lab, Inc. |
Multivalent multispecific constructs for targeted payload delivery
|
|
WO2025199278A2
(en)
*
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked multispecific antigen-binding molecules with cleavable linkers
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|
|
WO2025237931A1
(en)
*
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
WO2025259871A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
WO2026024841A1
(en)
*
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|
|
WO2026060000A1
(en)
*
|
2024-09-11 |
2026-03-19 |
Triveni Bio, Inc. |
Dual inhibitor kallikrein antibodies and uses thereof
|
|
WO2026082031A1
(zh)
*
|
2024-10-14 |
2026-04-23 |
先声再明医药股份有限公司 |
一种包含抗cdh6抗体或其adc的药物组合物
|